Johnson and Johnson (J and J) has announced it will invest USD 2 billion in expanding its US manufacturing capacity over the next decade, responding to escalating concerns over trade and potential drug import tariffs.

The investment includes a 10-year agreement with Fujifilm Diosynth to operate a 160,000-square-foot biomanufacturing facility in Holly Springs, North Carolina, creating around 120 permanent jobs. The initiative supports broader efforts by J and J to bolster domestic production and mitigate potential supply disruptions.

This expansion builds on earlier commitments made by J and J to increase US investments by 25 percent, targeting more than USD 55 billion in manufacturing, research and development, and technology over the next four years. It complements other key ventures, including a planned USD 2 billion facility in Wilson, North Carolina, expected to generate 5,000 construction jobs and 500 permanent positions, focused on producing therapies for cancer, immune-mediated conditions, and neurological diseases.

The move reflects a growing trend among pharmaceutical firms responding to geopolitical uncertainty and potential tariff challenges by reshoring production and reinforcing onshore resilience.